LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,257 shares of the medical instruments supplier’s stock after selling 812 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in LeMaitre Vascular were worth $488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of LMAT. Driehaus Capital Management LLC grew its position in shares of LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares during the last quarter. F M Investments LLC purchased a new position in shares of LeMaitre Vascular during the second quarter worth approximately $7,443,000. Nicholas Investment Partners LP purchased a new position in shares of LeMaitre Vascular during the second quarter worth approximately $3,900,000. Janus Henderson Group PLC grew its position in shares of LeMaitre Vascular by 554.7% during the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares during the last quarter. Finally, Conestoga Capital Advisors LLC grew its position in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after acquiring an additional 36,850 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LMAT shares. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Oppenheimer reiterated an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Up 2.0 %

NASDAQ:LMAT opened at $107.97 on Monday. LeMaitre Vascular, Inc. has a fifty-two week low of $51.70 and a fifty-two week high of $108.09. The stock has a market cap of $2.43 billion, a PE ratio of 59.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.89. The firm’s fifty day simple moving average is $93.85 and its 200-day simple moving average is $86.91.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. During the same period in the prior year, the company posted $0.33 EPS. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. Equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.